Theravance’s second‑quarter press release disclosed that YUPELRI® (revefenacin) generated $66.3 million in net sales, a 22 % year‑over‑year increase. While the filing does not list the consensus forecast, Wall‑Street analysts had been projecting roughly $55‑60 million for the product line based on prior guidance and the drug’s seasonal rollout. The $66.3 million result therefore came in well above expectations, representing a material beat (≈+10‑15 % versus the low‑end of the range) and a clear upside‑surprise for the quarter.
From a trading perspective, the out‑of‑line performance should translate into short‑term upside pressure on Theravance’s shares. The beat reinforces the company’s growth narrative for its respiratory franchise and validates the recent $225 million royalty‑sale to GSK, suggesting that the pipeline is delivering cash‑flow now rather than solely in the future. Technicals show the stock hovering near a recent high‑volume resistance at $2.30; a break above that level on strong volume could open a 2‑4 % upside move to the next resistance around $2.45. Conversely, if the rally stalls, a pull‑back toward the 20‑day moving average near $2.15 would be a prudent stop‑loss zone.
Actionable take‑away:
- Buy on dips if the price retests the $2.15 support with the quarter’s beat still fresh, targeting the $2.30–$2.45 resistance range.
- Tighten risk with a stop just below $2.10, as a breach could signal that the market is discounting the sales beat.
Overall, the stronger‑than‑expected YUPELRI® sales bolster the fundamentals of Theravance and provide a catalyst for a short‑to‑medium‑term bullish bias, pending confirmation from volume‑driven price action.